Biokin Pharmaceutical (688506.SH): Yizekang included in the breakthrough therapy designation list

Zhitong Finance APP News, Baili Tianheng (688506.SH) announced that the company's independently developed globally first-in-class, novel-concept, and the world's first and only approved EGFRHER3 bispecific antibody-drug conjugate (ADC) Yizekang (lunkanilimab? / BL-B01D1/iza-bren) for the treatment of patients with recurrent or metastatic biliary tract cancer who have previously failed platinum-containing chemotherapy has been included in the breakthrough therapy designation list by the Center for Drug Evaluation (CDE) of the National Medical Products Administration, and the public notice has recently been completed. As of now, Yizekang has had 9 indications included in the CDE's breakthrough therapy designation list, and 1 indication granted breakthrough therapy designation by the U.S. Food and Drug Administration.